<drug type="biotech" created="2005-06-13" updated="2020-09-03">
  <drugbank-id primary="true">DB00088</drugbank-id>
  <drugbank-id>BTD00037</drugbank-id>
  <drugbank-id>BIOD00037</drugbank-id>
  <name>Alglucerase</name>
  <description>Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.</description>
  <cas-number>143003-46-7</cas-number>
  <unii>27T56C7KK0</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A136</ref-id>
        <pubmed-id>19265748</pubmed-id>
        <citation>Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S: Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009 Feb;11(2):92-100. doi: 10.1097/GIM.0b013e31818e2c19.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)</indication>
  <pharmacodynamics>Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of alglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside</pharmacodynamics>
  <mechanism-of-action>Alglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>3.6-10.4 min</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>* 49.4 to 282.1 mL/kg</volume-of-distribution>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Ceredase</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-1060</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-04-05</started-marketing-on>
      <ended-marketing-on>2011-04-01</ended-marketing-on>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>80 U/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020057</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Ceredase</name>
      <ingredients>Alglucerase</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Genzyme Inc.</name>
      <url>http://www.genzyme.ca</url>
    </packager>
    <packager>
      <name>Oso Biopharmaceuticals Manufacturing LLC</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Genzyme corp</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Ceredase 80 unit/ml vial</description>
      <cost currency="USD">380.64</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzyme Replacement Therapy</category>
      <mesh-id>D056947</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Gaucher Disease</category>
      <mesh-id>D005776</mesh-id>
    </category>
    <category>
      <category>Glucosidases</category>
      <mesh-id>D005959</mesh-id>
    </category>
    <category>
      <category>Glycoside Hydrolases</category>
      <mesh-id>D006026</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Hydrolytic Lysosomal Glucocerebroside-specific Enzyme</category>
      <mesh-id/>
    </category>
    <category>
      <category>Recombinant Proteins</category>
      <mesh-id>D011994</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>80 U/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>400 UI</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>50 UI</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AB01">
      <level code="A16AB">Enzymes</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00088.pdf?1265922796</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;DB00088 sequence
ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANH
TGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIR
VPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWT
SPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGL
LSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPE
AAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRG
MQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHL
GHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFL
ETISPGYSIHTYLWRRQ</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.168</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.41</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>55597.4</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2532H3854N672O711S16</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507500</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M16328</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164748093</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P04062</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Alglucerase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201633</identifier>
    </external-identifier>
    <external-identifier>
      <resource>RxCUI</resource>
      <identifier>46049</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/ceredase.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/alglucerase.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004806</id>
      <name>Glucocerebroside</name>
      <organism>Humans</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A95</ref-id>
            <pubmed-id>20301446</pubmed-id>
            <citation>Pastores GM, Hughes DA: Gaucher Disease .</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>